文献速递认知障碍与痴呆

不依赖APOE的阿尔茨海默病多基因风险评分与无症状老年人脑淀粉样蛋白沉积的关联

Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults.
PubMed 文献 · Neurology · 2022-08-01

研究纳入291名无症状老年人(含83名淀粉样蛋白阳性)及228名ADNI验证队列,评估排除APOE的阿尔茨海默病多基因风险评分与脑淀粉样蛋白负荷的关联。优化版oA-PRS与淀粉样蛋白状态显著相关(INSIGHT OR 5.26,ADNI OR 3.38),且在APOE ε4携带者中可准确区分淀粉样蛋白阳性与阴性。

要点

  • 排除APOE的优化多基因风险评分oA-PRS与无症状老年人脑淀粉样蛋白状态独立相关。
  • oA-PRS在APOE ε4携带者中区分淀粉样蛋白阳性的OR在INSIGHT为181.6,ADNI为44.94。
  • 不依赖APOE的多基因风险评分可能改善脑淀粉样蛋白的风险预测。

核心结论

  • 依赖AD遗传风险因素但排除APOE的多基因风险评分可能改善脑淀粉样蛋白的风险预测,允许不依赖APOE状态对认知正常AD风险个体进行分层。

研究设计与样本

  • 纳入INSIGHT pre-AD队列291名无症状老年参与者(含83名淀粉样蛋白阳性)进行淀粉样蛋白影像;A-PRS由33个AD风险变异组成并排除APOE,从中选出与淀粉样蛋白阳性关联最强的17个变异定义优化oA-PRS。
  • ADNI研究228名参与者(90名淀粉样蛋白阳性)作为验证队列;EADI纳入2300例AD患者和6994名对照进行评估。

主要发现

  • A-PRS在INSIGHT或ADNI队列中与淀粉样蛋白负荷无显著关联,无论是否校正APOE基因型。
  • oA-PRS与淀粉样蛋白状态显著关联且独立于APOE校正(INSIGHT OR 5.26 [1.71-16.88];ADNI OR 3.38 [1.02-11.63])。
  • oA-PRS可准确区分淀粉样蛋白阳性与阴性的APOE ε4携带者(INSIGHT OR 181.6 [7.53-10674.6];ADNI OR 44.94 [3.03-1277])。
  • A-PRS和oA-PRS在EADI队列中与疾病状态显著关联(OR分别为1.68 [1.53-1.85]和2.06 [1.73-2.45])。
  • oA-PRS变异所分配的基因富集于与β-淀粉样蛋白代谢和沉积相关的本体论。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Brain amyloid deposition, a major risk factor for Alzheimer disease (AD), is currently estimated by measuring CSF or plasma amyloid peptide levels or by PET imaging. Assessing genetic risks relating to amyloid deposition before any accumulation has occurred would allow for earlier intervention in persons at increased risk for developing AD. Previous work linking amyloid burden and genetic risk relied almost exclusively on APOE, a major AD genetic risk factor. Here, we ask whether a polygenic risk score (PRS) that incorporates an optimized list of common variants linked to AD and excludes APOE is associated with brain amyloid load in cognitively unimpaired older adults. METHODS: We included 291 asymptomatic older participants from the INveStIGation of AlzHeimer's PredicTors (INSIGHT pre-AD) cohort who underwent amyloid imaging, including 83 amyloid-positive (+) participants. We used an Alzheimer's (A) PRS composed of 33 AD risk variants excluding APOE and selected the 17 variants that showed the strongest association with amyloid positivity to define an optimized (oA) PRS. Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study (228 participants, 90 amyloid [+]) were tested as a validation cohort. Finally, 2,300 patients with AD and 6,994 controls from the European Alzheimer's Disease Initiative (EADI) were evaluated. RESULTS: A-PRS was not significantly associated with amyloid burden in the INSIGHT or ADNI cohorts with or without correction for the APOE genotype. However, oA-PRS was significantly associated with amyloid status independently of APOE adjustment (INSIGHT odds ratio [OR]: 5.26 [1.71-16.88]; ADNI OR: 3.38 [1.02-11.63]). Of interest, oA-PRS accurately discriminated amyloid (+) and (-) APOE ε4 carriers (INSIGHT OR: 181.6 [7.53-10,674.6]; ADNI OR: 44.94 [3.03-1,277]). A-PRS and oA-PRS showed a significant association with disease status in the EADI cohort (OR: 1.68 [1.53-1.85] and 2.06 [1.73-2.45], respectively). Genes assigned to oA-PRS variants were enriched in ontologies related to β-amyloid metabolism and deposition. DISCUSSION: PRSs relying on AD genetic risk factors excluding APOE may improve risk prediction for brain amyloid, allowing stratification of cognitively unimpaired individuals at risk of AD independent of their APOE status.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Xicota L, Gyorgy B, Grenier-Boley B, et al. Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults. Neurology. 2022. PMID: 35606148. doi:10.1212/WNL.0000000000200544

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。